Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The two companies have been involved in recent licensing deals.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
MK-6837 has been discontinued, the company discloses.
